What Is GI-MAP Test

The GI-MAP (Gastrointestinal Microbial Assay Plus) is a comprehensive stool test that uses quantitative polymerase chain reaction (qPCR) technology to identify and measure DNA from bacteria, viruses, parasites, and fungi in a fecal sample. It also includes markers of digestive capacity, intestinal inflammation, and immune function. The test is manufactured by Diagnostic Solutions Laboratory and is widely used within functional and integrative medicine settings.

The gastrointestinal tract houses the largest concentration of immune tissue in the body, produces a significant share of the body's neurotransmitters, and serves as a frontline barrier between the external environment and internal circulation. Dysfunction in any layer of this system, whether from chronic infection, dysbiosis, or compromised mucosal integrity, can cascade into systemic inflammation, nutrient malabsorption, hormonal disruption, and immune dysregulation. Because these downstream effects often manifest as fatigue, brain fog, skin issues, or autoimmune flares rather than obvious GI symptoms, the root cause can remain hidden without targeted assessment.

For those focused on longevity, maintaining gut integrity matters because chronic low-grade inflammation originating from the intestinal lining is a recognized driver of biological aging. A test that can quantify specific pathogens, measure immune markers like secretory IgA, and evaluate digestive enzyme output provides a functional baseline that standard bloodwork simply cannot capture. Identifying and correcting gut imbalances early can reduce inflammatory burden, improve nutrient absorption, and support the immune and metabolic systems that underpin healthspan.

The GI-MAP relies on quantitative PCR, a molecular technique that amplifies specific segments of microbial DNA in a stool sample. Rather than attempting to grow organisms on culture media, qPCR targets known genetic sequences unique to each pathogen, commensal bacterium, parasite, or fungal species. The "quantitative" element means the test does not merely report whether an organism is present; it reports how much DNA is detected, expressed in numerical values that can be compared against reference ranges. This allows clinicians to distinguish between a low-level colonization that may be clinically insignificant and a high-load infection that warrants treatment.

The test panel is organized into several categories. Pathogen targets include bacteria such as Helicobacter pylori (with virulence factors like CagA and VacA), Clostridioides difficile, Campylobacter, and Salmonella; parasites such as Giardia, Cryptosporidium, and Entamoeba histolytica; and viruses including norovirus and adenovirus. Opportunistic organisms, those that may be normal in small amounts but problematic when overgrown, are listed separately and include Candida species, Staphylococcus aureus, Pseudomonas, and several others. A commensal bacteria section profiles beneficial organisms like Lactobacillus, Bifidobacterium, and Akkermansia muciniphila, providing a snapshot of the microbiome's overall composition.

Beyond microbial identification, the GI-MAP includes functional markers. Pancreatic elastase reflects exocrine pancreatic function and the ability to digest protein and fat. Steatocrit measures fecal fat content, indicating fat malabsorption. Beta-glucuronidase is an enzyme produced by certain gut bacteria that can reactivate estrogen and toxins that the liver has already conjugated for excretion. Calprotectin and lactoferrin serve as markers of intestinal inflammation. Secretory IgA reflects mucosal immune status, while anti-gliadin IgA can flag gluten-related immune activation. Zonulin, included in some panels, provides an indirect measure of intestinal permeability.

The GI-MAP measures microbial DNA across several categories: bacterial pathogens (H. pylori with virulence factors, C. difficile toxins A and B, Campylobacter, Salmonella, Shigella, and others), parasitic pathogens (Giardia lamblia, Cryptosporidium, Entamoeba histolytica, and additional protozoa and helminths), viral pathogens (norovirus, rotavirus, adenovirus), and fungal organisms (Candida albicans and other Candida species). Beyond frank pathogens, the panel profiles opportunistic bacteria such as Klebsiella pneumoniae, Proteus mirabilis, Staphylococcus aureus, and Pseudomonas aeruginosa, organisms that are normal in small quantities but can contribute to disease when overgrown.

The commensal bacteria section quantifies beneficial organisms including Lactobacillus species, Bifidobacterium species, Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Akkermansia muciniphila. These values help clinicians assess the overall balance and diversity of the resident microbiome.

Functional and immune markers round out the panel. Pancreatic elastase evaluates the pancreas's ability to produce digestive enzymes. Steatocrit reveals the degree of fat malabsorption. Beta-glucuronidase measures bacterial enzymatic activity that can interfere with hormone and toxin clearance. Secretory IgA reflects mucosal immune defense. Calprotectin and lactoferrin quantify intestinal inflammation. Anti-gliadin IgA screens for gluten-related immune reactivity, and zonulin (on some panel versions) provides an indirect assessment of intestinal permeability.

Preparation for the GI-MAP focuses on minimizing factors that could suppress microbial loads or alter marker levels. Ideally, patients should discontinue antimicrobial supplements (such as oregano oil, berberine, or allicin), probiotics, and digestive enzyme supplements for at least two weeks before collection. Prescription antibiotics should be finished at least four weeks prior, unless a clinician determines that testing during treatment is specifically useful. Proton pump inhibitors and bismuth-containing products (such as Pepto-Bismol) can also affect results and should be discussed with the ordering practitioner.

The collection itself uses a single stool sample deposited into the provided tube, which contains a preservative solution. The sample does not need to be the first bowel movement of the day, but it should be collected into a clean container and transferred to the tube promptly. Avoid contaminating the sample with urine or toilet water. Once sealed, the tube is placed in the insulated shipping box with a cold pack and shipped to the laboratory via the provided prepaid label. The sample is stable in the preservative solution for several days, but shipping on a weekday (ideally Monday through Wednesday) reduces the chance of the sample sitting in transit over a weekend.

GI-MAP results are reported as numerical values alongside reference ranges designated as normal, borderline, or high. Pathogen markers are typically interpreted as positive or negative, though the quantitative data can indicate the severity of an infection. A high-load H. pylori reading with positive CagA and VacA virulence factors, for example, carries different clinical weight than a borderline detection without virulence markers.

Opportunistic organisms require careful contextual reading. A mildly elevated Candida level in someone without symptoms may not warrant treatment, while the same reading in someone with chronic bloating, sugar cravings, and oral thrush gains clinical significance. Commensal bacteria levels that fall below the normal range can indicate dysbiosis, antibiotic-related depletion, or inadequate prebiotic fiber intake, and help guide probiotic and dietary recommendations.

Functional markers add interpretive depth. Low pancreatic elastase suggests the need for digestive enzyme support and further evaluation of pancreatic health. Elevated beta-glucuronidase may explain estrogen dominance symptoms or poor toxin clearance and can be addressed with calcium-D-glucarate or targeted dietary interventions. Low secretory IgA points to a suppressed mucosal immune response, often seen in chronic stress or prolonged illness. Elevated calprotectin warrants further investigation, as it can indicate inflammatory bowel disease or significant mucosal inflammation. The report is most useful when a clinician reads these markers together as a system rather than reacting to each value in isolation.

For most people, the GI-MAP is ordered as an initial assessment followed by a retest three to six months after completing a treatment protocol. The retest confirms whether targeted pathogens have been eradicated, opportunistic organisms have been reduced, and commensal populations have recovered. Retesting too early (for instance, four weeks after finishing an antimicrobial protocol) may not allow enough time for the microbiome to restabilize and can produce misleading results.

For individuals managing chronic conditions such as autoimmune disease, recurrent SIBO, or mold-related illness, annual or biannual testing may be appropriate as part of ongoing monitoring. In the absence of active symptoms or a specific clinical question, routine periodic testing is generally unnecessary. The test is most valuable when it answers a specific clinical question or tracks the trajectory of a known imbalance, rather than as a screening tool for asymptomatic individuals.

The qPCR methodology underpinning the GI-MAP is well-established in molecular diagnostics and is used across clinical microbiology, not just in functional medicine contexts. Studies comparing PCR-based stool pathogen detection to traditional culture methods consistently show higher sensitivity and specificity for qPCR, particularly for organisms like Giardia, Cryptosporidium, and Clostridioides difficile that are notoriously difficult to culture. The individual markers on the panel, such as calprotectin for inflammatory bowel disease screening and pancreatic elastase for exocrine pancreatic insufficiency, have their own bodies of validation research in gastroenterology literature.

That said, some aspects of the GI-MAP lack the same depth of clinical validation. The reference ranges for opportunistic organisms and commensal bacteria are established by the laboratory itself and do not always align with ranges published in peer-reviewed research. The clinical significance of mildly elevated opportunistic bacteria in the absence of symptoms remains debated. While the test is widely used in functional and integrative medicine, it has not been adopted by mainstream gastroenterology guidelines, partly because large-scale clinical trials evaluating whether GI-MAP-guided treatment protocols improve outcomes compared to standard approaches have not been conducted. The test is best understood as a clinically useful tool whose individual components are well-validated, even though the composite panel as a proprietary product has less independent published research behind it.

The GI-MAP is a low-risk diagnostic test involving only stool collection, with no physical side effects. The primary risk is misinterpretation: acting on mildly elevated markers without clinical context can lead to unnecessary antimicrobial treatment, which may itself disrupt the microbiome. False negatives are possible if sample collection or shipping conditions are suboptimal, or if antimicrobial agents are taken too close to the collection date. The test is not covered by most insurance plans and typically costs between several hundred dollars, which may need to be weighed against its clinical utility for any given patient. Results should be interpreted by a practitioner with training in functional gastrointestinal assessment.